LEARNCTMM’s¬†LEARN project (2009-2014) aimed to develop new instruments that enable an earlier and more reliable diagnosis of Alzheimer’s Disease (AD) during life. We developed a decision analytic model for the evaluation of advanced biomarkers for AD in mild cognitive impairment. In combination with a hypothetical disease-modifying treatment we¬†evaluated the position of advanced biomarkers in clinical practice when treatment becomes available.


  • Handels RL, Aalten P, Wolfs CA, OldeRikkert M, Scheltens P, Visser PJ, Joore MA, Severens JL, Verhey FR. Diagnostic and economic evaluation of new biomarkers for Alzheimer’s disease: the research protocol of a prospective cohort study. BMC Neurol. 2012 Aug 10;12:72. PubMed.
  • Handels RL, Joore MA, Tran-Duy A, Wimo A, Wolfs CA, Verhey FR, Severens JL. Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer’s disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment. Alzheimers Dement. 2015 Aug;11(8):896-905. doi: 10.1016/j.jalz.2015.02.009. PubMed.
  • CTMM’s LEARN outcomes report.
  • A simple version of this model is available open source at www.smard.org.